Cite
HARVARD Citation
Latagliata, R. et al. (2021). Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Hematological oncology. 39 (3), pp. 401-408. [Online].